5 Stocks Options Traders Should Watch Today

Beginning today, the International Securities Exchange (ISE) will begin listing options on Wall Street newcomers Bojangles Inc (NASDAQ:BOJA), Party City Holdco Inc (NYSE:PRTY), and Virtu Financial Inc (NASDAQ:VIRT). Additionally, a number of biotechs will begin trading options, including Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) and Diplomat Pharmacy Inc (NYSE:DPLO). Here's a quick roundup of how BOJA, PRTY, VIRT, EPRS, and DPLO have been performing on the charts in the lead-up to today's big event.

Fast-food concern BOJA began trading on May 8, after pricing its initial public offering (IPO) at $19 . The stock popped as high as $27.97 on its first day of trading -- and rallied to a post-IPO peak of $28.45 on May 14 -- but settled last night at $25.32.

PRTY's IPO was priced at $17, and when the shares began trading on April 16, they rose to an intraday peak of $20.84. The party supply specialist hit its highest perch to date of $22.60 on May 13, just before reporting earnings, and was last seen lingering near $21.83.

VIRT priced its IPO at $19 per share, before jumping to $23.67 on April 16, its first day of trading. Shares of the financial firm went on to hit an all-time intraday peak of $24.25 on April 20 -- a quarter more than its average 12-month price target -- but have since retreated to the $22 area.

Meanwhile, among the biotechs dipping their toes into the options market tomorrow is EPRS. The stock has been a long-term laggard -- shedding 43% on a year-over-year basis. More recently, the security's early March rally attempt was halted in the $12 region -- a speed bump for roughly a year -- with the shares last seen much lower, at $5.94. Analysts have kept the faith, though, with all three brokerage firms maintaining a "strong buy" rating. Plus, the average 12-month price target of $13 rests in territory not seen since last June..

DPLO, on the other hand, has rallied more than 30% year-to-date, and hit its highest perch on record in late April. Last night, the stock settled at $35.68 -- about 11% below the consensus 12-month price target of $40. Meanwhile, although the equity has been making strong strides on the charts, and recently upped its full-year guidance, short interest accounts for a healthy 9.5% of the stock's available float, and would take eight sessions to cover, at DPLO's average daily pace of trading.

Elsewhere in the biotech sphere, Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Cara Therapeutics Inc (NASDAQ:CARA), Coherus Biosciences Inc (NASDAQ:CHRS), CorMedix Inc. (NYSEMKT:CRMD), Immune Design Corp (NASDAQ:IMDZ), Invivo Therapeutics Holdings Corp (NASDAQ:NVIV), SAGE Therapeutics Inc (NASDAQ:SAGE), Spark Therapeutics Inc (NASDAQ:ONCE), Verastem Inc (NASDAQ:VSTM), and Vital Therapies Inc (NASDAQ:VTL) will also begin trading options today.